Shanghai, China, November 3, 2021 – Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai [1] as an important step towards strengthening its discovery platform to facilitate the development and delivery of innovative ophthalmic therapies.
Arctic Vision's leadership team and science team at JLABS @ Shanghai - rented lab
Established in 2019, Arctic Vision aims to discover, develop and deliver innovative ophthalmic therapies and eyecare products through in-licensing, co-development, and in-house R&D. “Over the past two years, we’ve built a product spectrum spanning from cutting-edge technologies to consumer-oriented technologies through the first two paths, and embarked on the third by establishing an in-house Science & Research team on a global basis.” said Dr. Eddy (Hoi Ti) Wu, Founder and CEO of Arctic Vision. “With the facility and global resources of JLABS, we feel we’ll be better equipped to move forward the development of our in-house scientific discovery platform, and to hopefully bring truly innovative therapies to ophthalmic patients in China, Asia and the world.”
“We’re excited to join JLABS @ Shanghai, which we feel can give us an edge to leverage its extensive network of resources and strengthen our overall capability of product development.”Actic Vision noted, “The infrastructural foundation provided with JLABS can enable us to explore more sophisticated and diversified science and research initiatives, ranging from target selection to platform collaboration, with goals to not only address the pressing unmet needs for ophthalmic patients worldwide, but also deliver solutions that can benefit patients during clinical processes and in their daily lives.”
Arctic Vision's leadership team and science team at JLABS @ Shanghai - office area
About Arctic Vision
Arctic Vision is a China-based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre-clinical stage to commercial stage products. Our vision is to provide innovative therapies in China, Asia and globally to address unmet clinical needs and benefit ophthalmic patients at large. Arctic Vision is supported by top-tier life sciences investors and led by an elite team of ophthalmic industry veterans with substantial regional and global experiences in R&D and commercialization of ophthalmic products. For more information, please visit www.arcticvision.com.
Investor and Media Contact
communications@arcticvision.com
[1]JLABS @ Shanghai is operated and managed by Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd.
